title: Predictive Value of Malignancy Risk Indices for Ovarian Masses in Premenopausal and Postmenopausal Women.
abstract: To evaluate the predictive role of a risk of malignancy index in discriminating between benign and malignant adnexal masses preoperatively.
  
  
  
  A total of 408 patients with adnexal masses managed surgically between January 2010 and February 2014 were included. The risk of malignancy indices (RMI) 1, 2, 3 and 4 were calculated using findings for ultrasonography, menopausal status, and CA125 levels. Histopathologic results were the end point. ROC analysis was used for the sensitivity and the specificity of the models.
  
  
  
  Some 37.6 % of the cases were malignant in the postmenopausal group while 7.9 % were malignant in the premenopausal group. Pelvic pain was the most common complaint, and the majority of the cases were diagnosed at stage 3. The RMI 1, 2, 3 and 4 yielded percentage sensitivities of 76.1, 79.1, 76.1 and 76.1 and specificities of 91.5, 89.1, 90.6, 88.6, respectively. RMI 1 was the most reliable test in the general population according to AUC levels and Kappa statistics. From ROC analysis results of post/ premenopausal women, the RMI 1 (cut off: 200) yielded sensitivities of 84.0/60.9 and specificities of 87.7/92.5. With RMI 2 they were 88.6/60.9 and 80.0/91.0, with RMI 3 84.0/ 60.9 and 87.7/91.8, and with RMI 4 (cut off:400) 81.8/47.8 and 83.6 /44.0. Although test performance of RMI methods were good in a general population and postmenopausal women, the RMI inter-agreement validity was only moderate or fair in premenopausal women.
  
  
  
  Our study confirms the effectiveness of RMI algorithms in postmenopausal women. However, more sensitive tests are needed for premenopausal women.
authors.affiliation: Gynecology and Obstetrics Clinic, Haydarpaşa Numune Training and Research Hospital, Istanbul E-mail : ertassinem@gmail.com.
authors.forename: Sinem
authors.initials: S
authors.lastname: Ertas
authors.forename: Fisun
authors.initials: F
authors.lastname: Vural
authors.forename: Fisun
authors.initials: F
authors.lastname: Vural
authors.forename: Ertugrul Can
authors.initials: EC
authors.lastname: Tufekci
authors.forename: Ahmet Candost
authors.initials: AC
authors.lastname: Ertas
authors.forename: Gultekin
authors.initials: G
authors.lastname: Kose
authors.forename: Nurettin
authors.initials: N
authors.lastname: Aka
mesh_terms: D000291:Adnexal Diseases / Q000150:complications*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010049:Ovarian Diseases / Q000150:complications*; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000209:etiology; D017698:Postmenopause; D011237:Predictive Value of Tests; D017697:Premenopause; D012372:ROC Curve; D012189:Retrospective Studies; D018570:Risk Assessment; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor